See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Liberation Day
Donald Trump
Natural Disasters
Trade War
Social Media
Stock Markets
Trade
Taxes
Climate Change
Artificial Intelligence
Nintendo
Published • loading... • Updated

iOnctura doses first subject in Phase II uveal melanoma treatment trial

Summary by Clinical Trials Arena
iOnctura has dosed the first subject in the Phase II OCULE-01 trial of oral roginolisib in individuals with metastatic uveal melanoma (UM).The post iOnctura doses first subject in Phase II uveal melanoma treatment trial appeared first on Clinical Trials Arena.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
Clinical Trials ArenaClinical Trials Arena

iOnctura doses first subject in Phase II uveal melanoma treatment trial

iOnctura has dosed the first subject in the Phase II OCULE-01 trial of oral roginolisib in individuals with metastatic uveal melanoma (UM).The post iOnctura doses first subject in Phase II uveal melanoma treatment trial appeared first on Clinical Trials Arena.

Read Full Article
Optimum Strategic CommunicationsOptimum Strategic Communications

iOnctura commences randomized Phase II study in metastatic uveal melanoma – Optimum Strategic Communications

First patient dosed in Phase II OCULE-01 study with roginolisib, an allosteric modulator of PI3Kδ The European Medicines Agency (EMA) has granted Orphan Drug Designation for roginolisib for treatment of uveal melanoma – benefits include 10 years market exclusivity in the European Union Geneva, Switzerland and Amsterdam, The Netherlands, 20 March 2025 – iOnctura, a […]

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Optimum Strategic Communications broke the news in on Thursday, March 20, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Geneva, Switzerland

Geneva, Switzerland

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal